Altreno (Tretinoin) Patent Expiration, LOE Window & CMS Spending

Altreno (Tretinoin) by Bausch Health: FDA Orange Book LOE 2038-08-22, 25 AB generics, $244K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN209353 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-08-22
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors25
2024 CMS Total Public Spend$244K
2024 Medicare Part D Spend$92K
2024 Medicaid Spend$152K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.